Filtered By:
Condition: Chronic Kidney Disease
Therapy: Dialysis
This page shows you your search results in order of date. This is page number 14.
Order by Relevance | Date
Total 325 results found since Jan 2013.
Lipids, Apolipoproteins, and Risk of Atherosclerotic Cardiovascular Disease in Persons With CKD
ConclusionsHigher VLDL-C and Apo-B levels, as well as lower HDL-C and Apo-AI levels, are associated with increased risk for ASCVD. These findings support future investigations into pharmacologic targeting of lipoproteins beyond LDL-C, such as triglyceride-rich lipoproteins, to reduce residual risk for ASCVD among individuals with CKD.
Source: American Journal of Kidney Diseases - January 25, 2019 Category: Urology & Nephrology Source Type: research
Demystifying the Benefits and Harms of Anticoagulation for Atrial Fibrillation in Chronic Kidney Disease.
This article aims to present a contemporary literature review of the benefits versus harms of anticoagulation in atrial fibrillation for patients with CKD stages 3, 4, 5, and 5 on dialysis. Although unanswered questions and areas of clinical equipoise remain, this piece serves to assist physicians in interpreting the complex body of literature and applying it to their clinical care.
PMID: 30593489 [PubMed - as supplied by publisher]
Source: Clinical Journal of the American Society of Nephrology : CJASN - December 28, 2018 Category: Urology & Nephrology Authors: Garlo KG, Steele DJR, Nigwekar SU, Chan KE Tags: Clin J Am Soc Nephrol Source Type: research
Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)
ConclusionsDespite initiating dialysis therapy with a higher hemoglobin level, prior treatment with darbepoetin was not associated with a reduction in mortality, myocardial infarction, or heart failure in the first 180 days, but a higher frequency of stroke was observed. In the absence of more definitive data, this may inform decisions regarding the use of erythropoiesis-stimulating agents to treat mild to moderate anemia in patients with type 2 diabetes and chronic kidney disease nearing dialysis therapy initiation.
Source: American Journal of Kidney Diseases - December 19, 2018 Category: Urology & Nephrology Source Type: research
IJERPH, Vol. 15, Pages 2733: Statins and Cardiovascular Disease Outcomes in Chronic Kidney Disease: Reaffirmation vs. Repudiation
orris
Cardiovascular disease (CVD) burden is several-fold higher in patients with chronic kidney disease (CKD). Although statins have been shown to provide significant CVD benefits in both the general population and patients with CKD, this has not translated into survival advantage in patients with advanced CKD or on dialysis. It has been reported that CVD risk continues to escalate as CKD progresses to end-stage kidney disease (ESKD); however, the CVD risk reduction by statins appears to decline as patients’ progress from the early to later stages of CKD. Statins have also been associated with a higher i...
Source: International Journal of Environmental Research and Public Health - December 4, 2018 Category: Environmental Health Authors: Chamberlain I. Obialo Elizabeth O. Ofili Keith C. Norris Tags: Review Source Type: research
Mortality of diabetic on chronic dialysis in Tunisia.
This study aims to specify the epidemio-logical, clinical, and biological characteristics of diabetic disease, chronic kidney disease (CKD), and comorbidities at the initiation of HD and investigate factors associated with mortality during the dialysis period. We retrospectively analyzed the outcome of diabetic patients who were initiated on HD from 2007 to 2012 at the Rabta Hospital of Tunis. During the follow-up period, all morbid events and deaths were recorded. Univariate analysis and multivariate analysis were performed to identify risk factors associated with mortality in our population. The study population included...
Source: Saudi Journal of Kidney Diseases and Transplantation - November 1, 2018 Category: Urology & Nephrology Authors: Jebali H, Laifi M, Mami I, Khadhar M, Chirmiti M, Beji S, Rheder R, Smaoui W, Krid M, Hmida FB, Rais L, Fatma LB, Zouaghi MK Tags: Saudi J Kidney Dis Transpl Source Type: research
Serum Glutaredoxin Activity as a Marker of Oxidative Stress in Chronic Kidney Disease: A Pilot Study
Conclusion: Our pilot study indicates that Grx may be a useful marker for assessing the degree of oxidative stress in CKD, however this needs further investigation in a larger prospective patient cohort.Nephron
Source: Nephron - October 5, 2018 Category: Urology & Nephrology Source Type: research
Early Outcomes After Branched and Fenestrated Endovascular Aortic Repair in Octogenarians.
CONCLUSIONS: Complex endovascular repair in octogenarians has higher early all cause mortality compared with non-octogenarians. Rupture and higher ASA class of ≥4 are independent predictors for early mortality. Age ≥80 years was found to be an independent predictor for higher early all cause mortality.
PMID: 30241980 [PubMed - as supplied by publisher]
Source: PubMed: Eur J Vasc Endovasc ... - September 18, 2018 Category: Surgery Authors: Makaloski V, Kölbel T, Rohlffs F, Behrendt CA, Law Y, Debus ES, Tsilimparis N Tags: Eur J Vasc Endovasc Surg Source Type: research
Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).
CONCLUSIONS: In studies of adults with CKD G5D treated with dialysis, sevelamer may lower death (all causes) compared to calcium-based binders and incur less treatment-related hypercalcaemia, while we found no clinically important benefits of any phosphate binder on cardiovascular death, myocardial infarction, stroke, fracture or coronary artery calcification. The effects of binders on patient-important outcomes compared to placebo are uncertain. In patients with CKD G2 to G5, the effects of sevelamer, lanthanum, and iron-based phosphate binders on cardiovascular, vascular calcification, and bone outcomes compared to place...
Source: Cochrane Database of Systematic Reviews - August 22, 2018 Category: General Medicine Authors: Ruospo M, Palmer SC, Natale P, Craig JC, Vecchio M, Elder GJ, Strippoli GF Tags: Cochrane Database Syst Rev Source Type: research
Cause-Specific Mortality in Patients with Chronic Kidney Disease and Atrial Fibrillation
Conclusions: In a non-dialysis-dependent CKD population, the presence of AF was associated with higher all-cause and cardiovascular mortality. These data suggest that patients with both CKD and AF are at high cardiovascular risk, and thus clinical practice (or trials) should aim at reducing the overall excess cardiovascular mortality (not stroke alone) in patients with AF and CKD.Am J Nephrol 2018;48:36 –45
Source: American Journal of Nephrology - July 26, 2018 Category: Neurology Source Type: research
Cause-Specific Mortality in Patients with Chronic Kidney Disease and Atrial Fibrillation.
CONCLUSIONS: In a non-dialysis-dependent CKD population, the presence of AF was associated with higher all-cause and cardiovascular mortality. These data suggest that patients with both CKD and AF are at high cardiovascular risk, and thus clinical practice (or trials) should aim at reducing the overall excess cardiovascular mortality (not stroke alone) in patients with AF and CKD.
PMID: 30048961 [PubMed - as supplied by publisher]
Source: American Journal of Nephrology - July 26, 2018 Category: Urology & Nephrology Authors: Airy M, Schold JD, Jolly SE, Arrigain S, Bansal N, Winkelmayer WC, Nally JV, Navaneethan SD Tags: Am J Nephrol Source Type: research
Variability in Non–Vitamin K Antagonist Oral Anticoagulants Dose Adjustment in Atrial Fibrillation Patients With Renal Dysfunction: The Influence of Renal Function Estimation Formulae
ConclusionsMDRD and CKD-EPI eGFR fail to correctly identify a significant proportion of patients who require NOAC dose adjustment, limiting their clinical utility. Cockcroft-Gault eCrCl should be calculated for all patients in whom a NOAC is being prescribed.RésuméContexteL’administration d’un nouvel anticoagulant oral non-antivitamine K (NACO) nécessite un ajustement de la dose en fonction des paramètres rénaux. La mesure de la fonction rénale la plus communément utilisée est le taux de filtration glomérulaire estimé (TFGe) selon la formule « Modified Diet in Renal Disease » (TFGe MDRD) ou « Chronic Kidne...
Source: Canadian Journal of Cardiology - July 24, 2018 Category: Cardiology Source Type: research
On-pump beating heart versus conventional coronary artery bypass grafting: comparative study on early and long-term clinical outcomes.
Conclusions: The OPB strategy may be as safe and effective as the conventional strategy during CABG among patients with similar risk profiles. A prospective randomized trial is warranted to better ascertain the beneficial impact of OPB-CABG as both a viable and a durable alternative strategy to C-CABG.
PMID: 29997927 [PubMed]
Source: Journal of Thoracic Disease - July 14, 2018 Category: Respiratory Medicine Tags: J Thorac Dis Source Type: research
Effects of physician's specialty on regular chronic kidney disease care in predialysis: A population-based cross-sectional study
Late referral in chronic kidney disease (CKD) is associated with irregular care and poor prognosis. How the specialty of healthcare provider affect late referral and irregular CKD care remain unclear.
We conducted a population-based cross-sectional study to include incident dialysis patients from 2002 to 2007 in Taiwan and observed for 1, 2, and 3 years before dialysis. The medical visits-related information was evaluated every 3 months, retrospectively. Irregular follow-up was defined as missing a follow-up during more than one interval every year.
A total of 46,626 patients were included. At 1, 2, and 3 years prior to ...
Source: Medicine - June 1, 2018 Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research
Safety and Efficacy of Apixaban Versus Warfarin in Patients With Advanced Chronic Kidney Disease.
Conclusion and Relevance: Patients with advanced CKD taking apixaban had similar bleeding rates at 3 months compared with those taking warfarin. However, those who continued therapy had higher major bleeding rates with warfarin between 6 and 12 months. This study provides knowledge on the effects of a direct oral anticoagulant in a population that was excluded from all major trials.
PMID: 29871510 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - June 1, 2018 Category: Drugs & Pharmacology Authors: Schafer JH, Casey AL, Dupre KA, Staubes BA Tags: Ann Pharmacother Source Type: research
Oral Anticoagulation in Chronic Kidney Disease and Atrial Fibrillation.
CONCLUSION: The cardiological societies' recommendation that patients with atrial fibrillation should be given oral anticoagulant drugs applies to the majority of such patients who also have chronic kidney disease.
PMID: 29789105 [PubMed - in process]
Source: Deutsches Arzteblatt International - May 24, 2018 Category: General Medicine Tags: Dtsch Arztebl Int Source Type: research
